Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. April 2021 18:20 ET | Quelle: Biogen Inc.

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...
28. April 2021 07:30 ET | Quelle: Biogen Inc.

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

Accelerated action on climate, health and equity, including new plastic-free packaging goals for finished goods by 20251Disclosed 2020 global pay equity analysis results2 and launched enhanced...
19. April 2021 07:30 ET | Quelle: Biogen Inc.

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA® (nusinersen)Additional research reinforces the potential of...
16. April 2021 07:30 ET | Quelle: Biogen Inc.

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus® (ocrelizumab)Real-world data from...
15. April 2021 16:30 ET | Quelle: Biogen Inc.

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needsMore than 500,000 individuals worldwide living with...
14. April 2021 16:06 ET | Quelle: Biogen Inc.

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease...
09. April 2021 16:30 ET | Quelle: Biogen Inc.

Biogen Announces Two New Nominees for Election to Board of Directors

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscienceCompany thanks Director Robert W. Pangia as he retires from the Board ...
08. April 2021 07:00 ET | Quelle: Biogen Inc.

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab)Biosimilars have the potential...
07. April 2021 07:30 ET | Quelle: Biogen Inc.

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option...
04. März 2021 07:47 ET | Quelle: Biogen Inc.

Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina

The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolioThe new facility is expected to employ approximately 90 people and to be...

Vorherige Seite